Compile Data Set for Download or QSAR
Report error Found 684 Enz. Inhib. hit(s) with Target = 'Vascular endothelial growth factor A'
TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282564(US9884843, Compound 1 | (R)-3-((4-bromo-2,2-difluo...)
Affinity DataEC50:  64nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282572((R)-3-((4-(difluoromethyl)-2,2-difluoro-3-hydroxy-...)
Affinity DataEC50:  62nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282578(US9884843, Compound 7)
Affinity DataEC50:  330nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282581(US9884843, Compound 9 | 4-Bromo-5-(3-chloro-5-fluo...)
Affinity DataEC50:  65nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282584(US9884843, Compound 11 | 4-Chloro-5-(3-chloro-5-fl...)
Affinity DataEC50:  125nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282598(US9884843, Compound 14 | 5-(3-Chloro-5-fluoropheno...)
Affinity DataEC50:  89nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282632(US9884843, Compound 25 | 5-(3-Chloro-5-fluoropheno...)
Affinity DataEC50:  29nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282634(US9884843, Compound 19 | 3-Amino-4-(difluoromethyl...)
Affinity DataEC50:  87nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282656(US9884843, Compound 22 | 4-(Difluoromethyl)-5-(3,5...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282682(US9884843, Compound 26 | 3-((3-Amino-4-(difluorome...)
Affinity DataEC50:  200nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282685(US9884843, Compound 40 | 3-((4-(Difluoromethyl)-2,...)
Affinity DataEC50:  14nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282697(US9884843, Compound 41 | (R)-3-((3-Amino-4-(difluo...)
Affinity DataEC50:  680nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282572((R)-3-((4-(difluoromethyl)-2,2-difluoro-3-hydroxy-...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282708(4-(Difluoromethyl)-5-(3,5-difluorophenoxy)-2,2- di...)
Affinity DataEC50:  90nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282708(4-(Difluoromethyl)-5-(3,5-difluorophenoxy)-2,2- di...)
Affinity DataEC50:  67nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282713(US9884843, Compound 57 | (R)-4-Bromo-5-(3-chloro-5...)
Affinity DataEC50:  45nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282731(US9884843, Compound 75 | (R)-4-bromo-5-((5-chlorop...)
Affinity DataEC50:  178nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282734(US9884843, Compound 78 | (R)-5-((4-Bromo-2,2-diflu...)
Affinity DataEC50:  330nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282741(US9884843, Compound 85 | (R)-3-((4-chloro-2,2-difl...)
Affinity DataEC50:  77nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282756(US9884843, Compound 100 | 5-(3,5-Difluorophenoxy)-...)
Affinity DataEC50:  18nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282761(US9884843, Compound 105 | 5-(3-cyano-5-fluoro-phen...)
Affinity DataEC50:  48nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282775(US9884843, Compound 119)
Affinity DataEC50:  31nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM301787(US9598370, Example 00128 | USRE47437, Example {[5-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataEC50:  4.21E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107699(US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  7.70E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM301799(US9598370, Example 00133 | USRE47437, Example {[5-...)
Affinity DataEC50:  4.30E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataEC50:  7.60E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataEC50:  1.50E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataEC50:  3.30E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataEC50:  1.40E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM301819(US9598370, Example 00143 | USRE47437, Example {[5-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM301820(US9598370, Example 00144 | USRE47437, Example ({3-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107714(US8722895, 20: {[5-(3-Cyanophenyl)-3-hydroxypyridi...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataEC50:  5.01E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM301825(US9598370, Example 00149 | USRE47437, Example ({3-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372960(US9896418, Compound 1 | US10597366, Compound 1)
Affinity DataEC50:  250nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372961(US9896418, Compound 2 | US10597366, Compound 2)
Affinity DataEC50:  62nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372964(US9896418, Compound 8 | US10597366, Compound 8)
Affinity DataEC50:  33nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US9896418, Compound 9 | US10597366, Compound 9)
Affinity DataEC50:  6nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US9896418, Compound 11 | US10597366, Compound 11)
Affinity DataEC50:  15nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US9896418, Compound 15 | US10597366, Compound 15)
Affinity DataEC50:  13nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372979(US9896418, Compound 17 | US10597366, Compound 17)
Affinity DataEC50:  160nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

Displayed 1 to 50 (of 684 total ) | Next | Last >>
Jump to: